A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

NCT06916091 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Eloralintide
DRUG: Placebo

Sponsor

Eli Lilly and Company